The use of riamilovir as part of combination antiviral therapy in adult population

In recent years, there has been a significant increase in the incidence of various viral infections among the adult population. These infections pose a serious threat to human health, as they can lead to the development of severe complications and even death. Antiviral therapy is a key element in the fight against these diseases, but existing drugs are often not effective enough. Therefore, the development of new, more effective and safe drugs is an urgent task of modern medicine. In this regard, the search for new approaches to the treatment of viral infections is becoming relevant, one of which may be the use of riamilovir as part of complex antiviral therapy. Riamilovir is an antiviral etiotropic drug that was developed specifically to combat RNA viral infections. It has a broad spectrum of action and is able to suppress the replication of viruses, thereby preventing their spread in the body. Riamilovir acts by blocking the enzymes necessary for the reproduction of the virus. This mechanism helps prevent further spread of the infection and speed up the patient’s recovery. The drug is well tolerated, and side effects are minimal, which makes it safe for use in patients with various concomitant pathologies. However, it is important to consider contraindications, such as individual intolerance to the components of the drug. The article provides a brief review of scientific literature devoted to the study of the effectiveness of antiviral complex therapy using the drug Riamilovir, and also presents a clinical observation of a patient with rapid relief of acute respiratory infection against the background of timely treatment.